Advances on pathogenesis of acquired peritoneal ultrafiltration failure in peritoneal dialysis / 中华肝脏病杂志

Peritoneal ultrafiltration failure is a common reason for peritoneal dialysis (PD) withdrawal as well as mortality in PD patients. Based on the three-pore system, inter-cellular small pores and trans-cellular ultra-small pores (aquaporin-1) are mainly responsible for water transfer across the peritoneum. Both small and ultra-small pores-dependent water (free water) transport decline accompanied with time on PD, with more significant decrease in free water, resulting in peritoneal ultrafiltration failure. The reduction of free water transport is associated with fast peritoneal solute transfer, reduced crystalloid osmotic gradient due to increased interstitial glucose absorption, and declined osmotic conductance to glucose resulted from impaired aquaporin-1 function and peritoneal interstitial fibrosis. The decline of small pore-based water is mainly because of fast loss of crystalloid osmotic gradient, decrease of hydrostatic pressure mediated by peritoneal vasculopathy, as well as reduced absolute number of small pores. The current review discusses the advance on pathogenesis of acquired peritoneal ultrafiltration failure in long-term PD.

Diálisis peritoneal de inicio urgente en pacientes con COVID-19 en una ciudad de gran altura / Urgent start peritoneal dialysis in patients with COVID-19 in a high rise city

Estimado director: La COVID-19 afecta a los pacientes con enfermedad renal crónica (ERC) en diálisis,1,2 ya que estos presentan factores de riesgo para desarrollar enfermedad grave, como diabetes mellitus, hipertensión arterial y edad mayor de 65 años. A esto se une la uremia, la inflamación crónica, el trastorno mineral óseo y la diálisis condicionan inmunosupresión crónica.3 La uremia produce cambios en la inmunidad innata y adaptativa y condiciona la disminución de la habilidad bactericida de los neutrófilos, la hiporeactividad de monocitos y diferenciación disminuida de células dendríticas, respuesta de células T alteradas, activación de la apoptosis inducida de células T y B, disminución de linfocitos B, cambios en la relación Th1/Th2 y disminución en número y actividad de células "natural killers".4,5 Además, en la ERC existe una alteración del sistema renina-angiotensina-aldosterona y de la relación ECA/ECA-2, que condiciona mayor susceptibilidad y peores resultados ante la infección por COVID-19.6 A pesar de ello, en diálisis, se ha reportado una cifra elevada de pacientes asintomáticos7 y también, síntomas gastrointestinales como náuseas, vómitos y diarrea,8,9 que son factores que provocan la diseminación de la enfermedad. Resalta la presencia de linfopenia y el patrón de vidrio esmerilado en gran número de pacientes, aunque también es frecuente la neumonía bilateral.6 Igualmente, los índices neutrófilo/linfocito y plaquetas/linfocitos se identifican como marcadores pronósticos tempranos de severidad de COVID-19 incluso en pacientes en hemodiálisis.10,11,12 Los pacientes con ERC deben continuar la terapia dialítica antes, durante o tras la infección por COVID-19. En ese sentido, se ha planteado que la diálisis peritoneal podría minimizar el riesgo de contraer la enfermedad por ser una terapia domiciliaria. Su uso en pacientes con falla renal y COVID-19 es segura, ya que brinda estabilidad hemodinámica, no precisa de anticoagulación ni de acceso vascular, puede iniciarse en forma aguda sin mayores complicaciones, disminuye la exposición del personal, puede ser monitorizada por teleconsulta y sus resultados son similares en comparación a las técnicas extracorpóreas.13,14,15 Presentamos nuestra experiencia en el manejo de cuatro pacientes con ERC, con infección por COVID-19 e iniciaron diálisis peritoneal, al no contar con hemodiálisis hospitalaria en su Centro Asistencial en Juliaca, Perú; ubicada a 3 827 metros sobre el nivel del mar. Dos de ellos eran hombres y tres tenían antecedente de hipertensión arterial. Los cuatro fueron hospitalizados en área COVID-19 y realizaron diálisis peritoneal manual, recibieron entrenamiento a cargo de la enfermera del programa por vía telefónica, por WhatsApp y mediante videos grabados previamente. Hubo complicaciones médicas y quirúrgicas relacionadas a la inserción del catéter en dos pacientes y se utilizó en forma aguda y urgente con un tiempo máximo de 36 h tras la cirugía. Las principales características de los pacientes se presentan en la tabla 1 y sus exámenes de laboratorio en la tabla 2. Al alta, dos de ellos...(AU)

Comparison of planned-start, early-start and deferred-start strategies for peritoneal dialysis initiation in end-stage kidney disease

INTRODUCTION@#In patients with end-stage kidney disease (ESKD) suitable for peritoneal dialysis (PD), PD should ideally be planned and initiated electively (planned-start PD). If patients present late, some centres initiate PD immediately with an urgent-start PD strategy. However, as urgent-start PD is resource intensive, we evaluated another strategy where patients first undergo emergent haemodialysis (HD), followed by early PD catheter insertion, and switch to PD 48-72 hours after PD catheter insertion (early-start PD). Conventionally, late-presenting patients are often started on HD, followed by deferred PD catheter insertion before switching to PD≥14 days after catheter insertion (deferred start PD).@*METHODS@#This is a retrospective study of new ESKD patients, comparing the planned-start, early-start and deferred-start PD strategies. Outcomes within 1 year of dialysis initiation were studied.@*RESULTS@#Of 148 patients, 57 (38.5%) patients had planned-start, 23 (15.5%) early-start and 68 (45.9%) deferred-start PD. Baseline biochemical parameters were similar except for a lower serum urea with planned-start PD. No significant differences were seen in the primary outcomes of technique and patient survival across all 3 subgroups. Compared to planned-start PD, early-start PD had a shorter time to catheter migration (hazard ratio [HR] 14.13, 95% confidence interval [CI] 1.65-121.04, P=0.016) while deferred-start PD has a shorter time to first peritonitis (HR 2.49, 95% CI 1.03-6.01, P=0.043) and first hospital admission (HR 2.03, 95% CI 1.35-3.07, P=0.001).@*CONCLUSION@#Planned-start PD is the best PD initiation strategy. However, if this is not possible, early-start PD is a viable alternative. Catheter migration may be more frequent with early-start PD but does not appear to impact technique survival.

Pseudoquiste peritoneal: una complicación inusual en paciente con diálisis peritoneal / Peritoneal pseudocysts: an unusual complication in a patient with peritoneal dialysis

Resumen Introducción: La terapia de sustitución renal con diálisis peritoneal es una modalidad segura para la enfermedad renal crónica terminal. Los resultados son comparables con pacientes en hemodiálisis por lo que lo hace una modalidad costo efectiva, especialmente en países en vía de desarrollo. Algunas complicaciones que se pueden presentar debido a diálisis peritoneal son: peritonitis, fuga, hernias, falla de filtración y disfunción del catéter. Una de las complicaciones infrecuentes de la diálisis peritoneal es la formación de un pseudoquiste peritoneal. Caso Clínico: Presentamos un caso de un paciente en terapia de sustitución renal con diálisis peritoneal, el cual presenta un pseudoquiste peritoneal como complicación de diálisis peritoneal.

Introduction: Renal replacement therapy with peritoneal dialysis is now a well-established, mature treatment modality for End-Stage Renal Disease. Patient outcomes with peritoneal dialysis are comparable than those with hemodialysis so does a more cost-effectiveness modality, especially in developing countries. Some complications of peritoneal dialysis are peritonitis, leaks, hernias, ultrafiltration failure, and catheter dislocation. One of the rare complications of peritoneal dialysis is peritoneal pseudocyst formation. Clinical Case: We report one such case of a patient with a history of renal replacement therapy managed on long-term peritoneal dialysis, which presents as a complication a peritoneal pseudocyst.

ABC de la diálisis peritoneal en pediatría / ABC of the peritoneal dialysis in pediatrics

Resumen: La enfermedad renal crónica terminal (ERCT) tiene una incidencia de 5,5 a 9 ppm, y una prevalencia de 23 a 65 ppm en menores de 15 años. La diálisis peritoneal (DP) crónica representa en pediatría la terapia de reemplazo renal más usada, previo al trasplante renal. Existen 2 tipos de DP crónicas, manual (DPCA) y automatizada (DPA), cuya elección se basa en las características del peritoneo eva luado mediante el test de equilibrio peritoneal (PET), que divide a los pacientes en transportadores altos (intercambio rápido), promedio alto, promedio bajo, y bajos (intercambio lento). Este test eva lúa básicamente el transporte de solutos, al cual se ha sumado el MiniPET, que evalúa el transporte peritoneal de agua libre. Se debe igualmente determinar la cuantía de diálisis (Kt/V), que representa la dosis de diálisis aplicada, con un valor mínimo sugerido de 1,7, relacionado a la morbimortalidad. Estos parámetros deben ser evaluados periódicamente para ajustar la DP, y cada vez que se sospeche una depuración o ultrafiltración inadecuadas. El objetivo de esta revisión es entregar conceptos bási cos sobre fisiología del transporte peritoneal, modalidades de DP, evaluación del transporte de agua y solutos peritoneal, y el cálculo de la dosis de diálisis para una diálisis ajustada a las necesidades de cada paciente, como también revisar los mecanismos de corrección y ajuste del procedimiento cada vez que se requiera.

Abstract: End-stage renal disease (ESRD) has an incidence of 5.5 to 9 pmp, and a prevalence of 23 to 65 pmp in children under 15 years of age. Chronic peritoneal dialysis (PD) represents the most widely used renal replacement therapy in children before kidney transplantation. There are two PD modalities, the manual one (CAPD) and the automated one (APD). The choice is based on the peritoneum characteristics, evaluated through the peritoneal equilibrium test (PET), which divides patients into high transporters (rapid exchange membrane), high average, low average, and low transporters (slow exchange membrane). This test basically evaluates the solutes transport rate, and the MiniPET has been added which evaluates peritoneal free water transport. The amount of dialysis (Kt/V), which represents the dose of dialysis administered also must be evaluated to assure a minimal value of 1.7 related to morbidity and mortality. These parameters should be evaluated periodically to ad just the PD and whenever suspected an inadequate clearance or ultrafiltration. The objective of this review is to provide basic concepts on peritoneal transport physiology, PD modalities, free water transport and peritoneal solute transport evaluation, and the dialysis dose to be applied according to the patient's needs, as well as reviewing the correction mechanisms and procedure adjustment whenever required.

Longitudinal changes in nutritional parameters and resting energy expenditure in end-stage renal disease / Alterações longitudinais nos parâmetros nutricionais e gasto energético de repouso na doença renal em estágio terminal

Abstract Aims: To evaluate the nutritional status, resting energy expenditure, caloric and protein intake, and evolution of biochemical parameters in three stages of chronic kidney disease: pre-dialytic, at the beginning of the dialysis treatment, and 30 days after starting treatment. Methods: The chi-square and Student's t tests were used to compare the variables, and analysis of repeated measurements was used to compare the data obtained in the three moments evaluated. The results were discussed at the 5% level of significance. Results: We evaluated 35 patients, 60% female and 60% with diabetes mellitus. There was a decrease in midarm circumference and serum albumin. Inflammatory state and caloric and protein intake increased. There was no significant difference in resting energy expenditure in the three moments. The serum urea and serum albumin, handgrip strength, and protein consumption after 30 days from the start of dialysis were greater in the peritoneal dialysis patients, when compared to the hemodialysis population. Conclusion: there was a decrease in midarm circumference and serum albumin and an increase in protein intake after dialysis. The peritoneal dialysis patients had higher muscle strength, even with lower protein intake. Resting energy expenditure was not different between dialysis methods and the moments evaluated.

Resumo Objetivos: Avaliar o estado nutricional, o gasto energético em repouso, o gasto calórico e proteico e a evolução dos parâmetros bioquímicos em três estágios da doença renal crônica: pré-dialítico, no início do tratamento dialítico e 30 dias após o início do tratamento. Métodos: O teste do qui-quadrado e o teste t de Student foram utilizados para comparar as variáveis, e a análise das medidas repetidas foi utilizada para comparar os dados obtidos nos três momentos avaliados. Os resultados foram discutidos ao nível de significância de 5%. Resultados: Foram avaliados 35 pacientes, 60% mulheres e 60% com diabetes mellitus. Houve uma diminuição na circunferência do terço médio do braço (CMB) e na albumina sérica. O estado inflamatório e a ingestão calórica e protéica aumentaram. Não houve diferença significativa no gasto energético em repouso nos três momentos. A ureia sérica e a albumina sérica, a força de preensão manual e o consumo de proteínas após 30 dias do início da diálise foram maiores nos pacientes em diálise peritoneal, quando comparados com a população em hemodiálise. Conclusão: houve diminuição da circunferência do terço médio do braço e na albumina sérica, e aumento da ingestão protéica após a diálise. Os pacientes em diálise peritoneal apresentaram maior força muscular, mesmo com menor consumo proteico. O gasto energético em repouso não foi diferente entre os métodos de diálise e os momentos avaliados.

Peritoneal Dialysis

SUMMARY Peritoneal dialysis (PD) is a renal replacement therapy based on infusing a sterile solution into the peritoneal cavity through a catheter and provides for the removal of solutes and water using the peritoneal membrane as the exchange surface. This solution, which is in close contact with the capillaries in the peritoneum, allows diffusion solute transport and osmotic ultrafiltration water loss since it is hyperosmolar to plasma due to the addition of osmotic agents (most commonly glucose). Infusion and drainage of the solution into the peritoneal cavity can be performed in two ways: manually (continuous ambulatory PD), in which the patient usually goes through four solution changes throughout the day, or machine-assisted PD (automated PD), in which dialysis is performed with the aid of a cycling machine that allows changes to be made overnight while the patient is sleeping. Prescription and follow-up of PD involve characterizing the type of peritoneal transport and assessing the offered dialysis dose (solute clearance) as well as diagnosing and treating possible method-related complications (infectious and non-infectious).

RESUMO A diálise peritoneal (DP) é uma terapia renal substitutiva baseada na infusão de uma solução estéril na cavidade peritoneal através de um cateter, proporcionando a remoção de solutos e água usando a membrana peritoneal como superfície de troca. Essa solução, em contato com os capilares do peritônio, permite o transporte difuso de solutos e a perda de água por ultrafiltração osmótica, uma vez que é hiperosmolar ao plasma devido à adição de agentes osmóticos (normalmente, a glicose). A infusão e drenagem da solução dentro da cavidade peritoneal pode ser realizada de duas maneiras: manualmente (DP ambulatorial contínua), em que o paciente, geralmente, passa por quatro trocas de solução durante o dia, ou por DP mecânica (automatizada), em que a diálise é realizada com o auxílio de uma máquina de diálise que permite que as trocas sejam feitas durante a noite, enquanto o paciente está dormindo. A prescrição e o acompanhamento da DP envolvem a caracterização do tipo de transporte peritoneal e a avaliação da dose de diálise oferecida (depuração do soluto), bem como o diagnóstico e tratamento de possíveis complicações relacionadas ao método (infecciosas e não infecciosas).

Strategies for Management of Peritoneal Dialysis Patients in Singapore during COVID-19 Pandemic

Peritoneal dialysis (PD) is the only well-established home-based dialysis therapy in Singapore. As it is a home-based modality, PD should be considered as a preferred mode of kidney replacement therapy (KRT) for patients with kidney failure during this COVID-19 pandemic as it avoids frequent visits to hospitals and/or satellite dialysis centres. The highly infectious nature of this virus has led to the implementation of the Disease Outbreak Response System Condition orange status in Singapore since early February 2020. This paper summarises the strategies for management of several aspects of PD in Singapore during this COVID-19 pandemic, including PD catheter insertion, PD training, home visit and assisted PD, outpatient PD clinic, inpatient management of PD patients with or without COVID-19 infection, PD as KRT for COVID-19 patients with acute kidney injury, management of common complications in PD (peritonitis and fluid overload), and management of PD inventory.

A call-to-action for sustainability in dialysis in Brazil / Um apelo pela sustentabilidade na diálise no Brasil

ABSTRACT Human-induced climate change has been an increasing concern in recent years. Nephrology, especially in the dialysis setting, has significant negative environmental impact worldwide, as it uses large amounts of water and energy and generates thousands of tons of waste. While our activities make us responsible agents, there are also several opportunities to change the game, both individually and as a society. This call-to-action intends to raise awareness about environmentally sustainable practices in dialysis and encourages this important discussion in Brazil.

RESUMO A mudança climática induzida pela atividade humana tem sido foco de preocupações crescentes nos últimos anos. A nefrologia, particularmente a diálise, produz significativos impactos ambientais em todo o mundo em virtude da grande utilização de água e energia e da geração de milhares de toneladas de resíduos. Embora nossas atividades nos tornem agentes responsáveis, há várias oportunidades para mudar esse cenário, tanto individualmente como em sociedade. O presente artigo pretende ampliar a conscientização sobre práticas ambientalmente sustentáveis em diálise e estimular essa importante discussão no Brasil.

Successful multiple-exchange peritoneal dialysis in a patient with severe hematological toxicity by methotrexate: case report and literature review / Diálise peritoneal com múltiplas trocas bem-sucedida em paciente com grave toxicidade hematológica por metotrexato: relato de caso e revisão de literatura

Abstract Methotrexate is an effective medication to control several diseases; however, it can be very toxic, being myelosuppression one of its main adverse effects, which increases in severity and frequency in patients with renal failure. We present the case of a 68-year-old man with chronic, end-stage renal disease associated with ANCA vasculitis, under treatment with peritoneal dialysis, who received the medication at a low dose, indicated by disease activity, which presented as a complication with severe pancytopenia with mucositis that improved with support measures and multiple-exchange peritoneal dialysis. We reviewed 20 cases published to date of pancytopenia associated with methotrexate in patients on dialysis and found high morbidity and mortality, which is why its use in this type of patient is not recommended. However, when this complication occurs, a therapeutic option could be the use of multiple-exchange peritoneal dialysis in addition to supportive therapy for drug-related toxicity, although it is recognized that studies are required to show the role of multiple-exchange peritoneal dialysis in the removal of this medication.

Resumo Apesar de sua toxicidade, o metotrexato é um medicamento eficaz no controle de várias doenças. A mielossupressão, um de seus principais efeitos adversos, aumenta em gravidade e frequência nos pacientes com insuficiência renal. Apresentamos o caso de um homem de 68 anos de idade com doença renal terminal relacionada à vasculite associada ao ANCA em diálise peritoneal, que recebeu a medicação em dose baixa em função da atividade da doença e que teve como complicação pancitopenia grave com mucosite, tratada com medidas de suporte e diálise peritoneal com múltiplas trocas. Revisamos 20 casos publicados até o presente momento sobre pancitopenia associada a metotrexato em pacientes em diálise. Foi identificada alta morbidade e mortalidade, razão pela qual seu uso nesse tipo de paciente não é recomendado. No entanto, quando esta complicação ocorre, uma opção terapêutica pode ser o uso de diálise peritoneal com múltiplas trocas, além da terapia de suporte para toxicidade medicamentosa. Maiores estudos são necessários para demonstrar o papel da diálise peritoneal com múltiplas trocas na remoção desse medicamento.

Comparison of three PET methods to assess peritoneal membrane transport

The peritoneal equilibration test (PET) is the most widespread method for assessing water and solute transport across the peritoneal membrane. This study compared three methods: traditional PET (t-PET), mini-PET, and modified PET (mod-PET). Non-diabetic adults (n=21) who had been on peritoneal dialysis (PD) for at least three months underwent t-PET (glucose 2.5%-4 h), mini-PET (glucose 3.86%-1 h), and mod-PET (glucose 3.86%-4 h) to determine dialysate-to-plasma concentration ratio (D/P) for creatinine and dialysate-to-baseline dialysate concentration ratio (D/D0) for glucose. Agreement between methods regarding D/P creatinine and D/D0 glucose was assessed using analysis of variance (ANOVA), Pearson's correlation coefficient, and Bland-Altman analysis. D/P creatinine differed between t-PET and mini-PET (P<0.001) and between mod-PET and mini-PET (P<0.01) but not between t-PET and mod-PET (P=0.746). The correlation of D/P creatinine with t-PET vs mod-PET was significant (r=0.387, P=0.009) but not that of t-PET vs mini-PET (r=0.088, P=0.241). Estimated bias was −0.029 (P=0.201) between t-PET and mod-PET, and 0.206 (P<0.001) between t-PET and mini-PET. D/D0 glucose differed between t-PET and mod-PET (P=0.003) and between mod-PET and mini-PET (P=0.002) but not between t-PET and mini-PET (P=0.885). The correlations of D/D0 glucose in t-PET vs mod-PET (r=−0.017, P=0.421) or t-PET vs mini-PET (r=0.152, P=0.609) were not significant. Estimated bias was 0.122 (P=0.026) between t-PET and mod-PET, and 0.122 (P=0.026) between t-PET and mini-PET. The significant correlation of D/P creatinine between t-PET and mod-PET suggested that the latter is a good alternative to t-PET. There was no such correlation between t-PET and mini-PET.

Prognostic factors in patients undergoing early-start peritoneal dialysis within 24 h after catheter insertion

This study aimed to investigate the clinical characteristics, prognosis, and factors for survival of patients who underwent early-start peritoneal dialysis (PD) within 24 h after catheter insertion three years after PD. This study was conducted from January 1, 2013 to December 31, 2017. All adult patients who were diagnosed with end-stage renal disease (ESRD) and underwent PD for the first time within 24 h after catheter insertion in our hospital were included. All patients with PD were followed-up until they withdrew from PD, switching to hemodialysis, were transferred to other medical centers, underwent renal transplantation, died or were lost to follow-up, or continued to undergo dialysis until the end of the study period. The follow-up observation lasted three years. The number of eligible patients was 110, and switching to hemodialysis and death were the main reasons for patients to withdraw from PD. The 1-, 2-, and 3-year technical survival rates of patients were 89.1, 79.1, and 79.1% respectively, while the 1-, 2- and 3-year survival rates were 90, 81.8, and 81.8%, respectively. The Charlson comorbidity index, age, hemoglobin, serum albumin, diabetic nephropathy, chronic glomerulonephritis, and hypertensive renal damage were independent risk factors that affected the prognosis of PD patients. Under the condition of ensuring the quality of the PD catheter insertion, early-start PD within 24 h after catheter insertion is a safe treatment approach for ESRD patients.

Experiencia en el tratamiento de la hemorragia uterina anormal en adolescentes con enfermedad renal crónica / Experience in the treatment of uterine hemorrhage in adolescents with chronic renal disease

Resumen: Introducción: La enfermedad renal crónica (ERC) se asocia con alteraciones menstruales, y el manejo del sangrado uterino suele ser complejo por las condiciones de este grupo de pacientes. El objetivo de este trabajo fue describir la respuesta clínica al tratamiento hormonal de las alteraciones menstruales de adolescentes con ERC. Métodos: Se presentan los datos de una serie de casos de pacientes adolescentes con ERC que cursaron con alteraciones menstruales y que recibieron tratamiento desde el año 2008 al 2012. Se identificaron las características del trastorno menstrual, del tratamiento hormonal recibido y de la respuesta al mismo. El análisis estadístico fue descriptivo. Resultados: Se estudiaron 11 pacientes de sexo femenino con edad promedio de 14.5 años, que se encontraban en prediálisis (n = 1), diálisis peritoneal (n = 7) y hemodiálisis (n = 3). Las pacientes presentaron hiperpolimenorrea asociada a la opsomenorrea (n = 3), en su mayoría clasificadas como hemorragia uterina anormal secundaria. El tratamiento, en general, fue con progestágenos de manera inicial (clormadinona con o sin medroxiprogesterona) o bien con anticonceptivos combinados. En la mayoría de las pacientes se obtuvo una respuesta favorable; sin embargo, hubo casos en los que fue necesario modificar la dosis y el tiempo de tratamiento. Conclusiones: La mayor parte de las adolescentes con ERC que han sido tratadas por hemorragia uterina anormal en nuestro estudio tuvieron una respuesta favorable al tratamiento hormonal.

Abstract: Background: Chronic kidney disease (CKD) is associated with menstrual abnormalities and management of uterine bleeding is often complex because of the conditions in this group of patients. The aim of this study was to describe the clinical response to hormonal treatment of menstrual alterations in adolescents with CKD. Methods: We present data of cases of adolescent patients with CKD who had undergone menstrual changes and received treatment during the period 2008 to 2012. The characteristics of the menstrual disorder, hormone treatment received, and response to treatment were evaluated. The statistical analysis aplicated to analyze the results was descriptive. Results: We studied 11 patients with a mean age of 14.5 years, who were in predialysis (n = 1), peritoneal dialysis (n = 7), hemodialysis (n = 3). Patients had hyperpolymenorrhea associated with opsomenorrhea (n = 3), mostly classified as secondary abnormal uterine bleeding. Treatment, in general, was with progestins initially (chlormadinone with or without medroxyprogesterone) or combined contraceptives. In the majority of the patients, a favorable response was obtained; however, there were cases where it was necessary to modify the dose and time of treatment. Conclusions: The majority of adolescents with CKD who have been treated for abnormal uterine bleeding in our study had a favorable response to hormonal treatment.

Compromiso cardiovascular en pacientes pediátricos en diálisis peritoneal crónica / Cardiovascular disease in pediatric patients under chronic peritoneal dialysis

La diálisis peritoneal (DP) es la terapia de reemplazo renal más usada en niños portadores de enfermedad renal crónica terminal. La enfermedad cardiovascular es la principal causa de mortalidad en estos pacientes. OBJETIVO: Caracterizar pacientes pediátricos en DP crónica desde el punto de vista cardiovascular. PACIENTES Y MÉTODO: Estudio de corte transversal en pacientes en DP, estables según criterios DOQI. Se registraron variables epidemiológicas, dialíticas, bioquímicas y cardiovasculares. Se evaluó hipertrofia ventricular izquierda (HVI) por ecocardiografía. El índice de masa ventricular izquierda (IMVI) se calculó por índice talla/edad (g/m2.7). Se consideró HVI > 38,6 g/m2.7, y severa HVI > 51 g/m2.7. Se analizaron las variables continuas mediante ANOVA, y categóricas por χ2 o método exacto de Fisher. Se analizaron los datos en STATA 11.0. RESULTADOS: Se incluyeron 21 pacientes, 11 varones, edad 9,2 ± 3,5 años. El diagnóstico más frecuente fue displasia renal (52%). El KtV residual promedio fue de 0,8, y peritoneal 1,9. En la ecocardiografía, un 52% presentó HVI, un 91% de ellos en rango severo. Se demostró una relación significativa entre ultrafiltración y presión arterial sistólica, y entre IMVI y hemoglobina (p < 0,05). CONCLUSIONES: En este estudio reportamos una incidencia de HVI mayor al 50%, en su mayoría grado severo, lo cual evidencia el importante compromiso cardiovascular en estos pacientes. La hipertensión arterial y falla de ultrafiltración destacan como importantes factores relacionados a la hipertrofia ventricular izquierda.

Peritoneal dialysis (PD) is the most common renal replacement therapy used in pediatric patients with end stage renal disease. This population has a mortality rate 1,000 times greater compare to pediatric population, mainly due to cardiovascular causes. OBJECTIVE: To characterize pediatric patients on chronic PD in relation to dialysis and cardiovascular outcome. PATIENTS AND METHODS: Cross sectional study. Patients in stable PD according to DOQI criteria were selected. Epidemiological, dialytic, biochemical and cardiovascular variables were registered. Left Ventricular Mass Index (LVMI) was calculated by height/age (g/m2.7). Left Ventricular Hypertrophy (LVH) was diagnosed with > 38.6 g/m2.7, severe LVH > 51 g/m2.7. Data were analyzed using STATA 11.0. continuous variables using ANOVA test and categorical variables were analyzed using χ2 test or Fisher's exact test. RESULTS: 21 patients, 11 males. Mean age 9.2 ± 3.52 years. The most frequent diagnosis was renal dysplasia (52%). Residual and Peritoneal KtV were 0.8 and 1.9 respectively. Fifty-two percent of patients showed LVH, 91% in severe range. A significant relationship between ultrafiltration/m2 and systolic blood pressure was depicted. Also a significant relationship between left ventricular mass index and hemoglobin (p < 0.05) was founded. CONCLUSIONS: The majority of the population showed left ventricular hypertrophy -particularly severe LVH-, which confirms an increased CV risk in this population. Blood pressure and loss of ultrafiltration were founded to be correlated to LVH.

Eje somatotrópico y marcadores moleculares del metabolismo mineral en niños en diálisis / Somatotropic axis and molecular markers of mineral metabolism in children undergoing chronic peritoneal dialysis

El retraso del crecimiento de los niños con enfermedad renal crónica es de origen multifactorial, incluyendo la resistencia a hormona de crecimiento (GH) y alteraciones en el metabolismo mineral óseo. Objetivos: 1) Caracterizar marcadores del metabolismo mineral: FGF23-Klotho y del eje somatotrópico: IGF1, IGFBP3 y GHBP, en niños en diálisis peritoneal (DP); 2) Evaluar la evolución de la talla en aquellos pacientes tratados con rhGH. Pacientes y Método: Niños prepuberales en DP seguidos durante 12 meses. Criterios exclusión fueron Tanner > 1, síndrome nefrótico activo, tratamiento esteroidal, malabsorción gastrointestinal, enfermedades endocrinas, síndromes genéticos, uso de rhGH al ingreso del estudio. Se evaluaron variables demográficas, antropométricas: Z talla/edad, (ZT/E), velocidad de crecimiento (VC), bioquímicas (calcio, fósforo, PTH), marcadores del metabolismo mineral (25OHvitD, 1,25OHvitD, FGF23, Klotho), y de crecimiento (IGF-1, IGFBP-3, GHBP). Resultados: Quince pacientes, 7 varones, edad 6,9 ± 3,0 años, tiempo en DP 14,33 ± 12,26 meses. Puntaje ZT/E al mes 1= -1,69 ± 1,03. FGF23: 131,7 ± 279,4 y Klotho: 125,9 ± 24,2 pg/ml. Durante los 12 meses de seguimiento no hubo diferencia significativa en el promedio de las variables. El uso de rhGH en 8 pacientes no mostró mejoría significativa del ZT/E ni la VC. El análisis bivariado mostró correlación positiva entre niveles de Klotho y delta ZT/E, y entre GHBP y VC (p < 0,05). Conclusiones: Los valores de FGF23 se encuentran elevados y los de Klotho disminuidos en niños con enfermedad renal crónica en DP en comparación con niños sanos. Las variables de eje somatotrópico, se encuentran normales o elevadas. rhGH tiende a mejorar la talla y GHBP se correlaciona positivamente con VC en estos niños.

Growth failure is one of the most relevant complications in children with chronic kidney disease (CKD). Among others, growth hormone (GH) resistance and bone mineral disorders have been identified as the most important causes of growth retardation. Objectives: 1. To characterize bone mineral metabolism and growth hormone bio-markers in CKD children treated with chronic peritoneal dialysis (PD). 2. To evaluate height change with rhGH treatment. Patients and Method: A longitudinal 12-month follow-up in prepuberal PD children. Exclusion criteria: Tanner stage >1, nephrotic syndrome, genetic disorders, steroids, intestinal absorption disorders, endocrine disturbances, treatment with GH to the entry of the study. Demographic and anthropometric data were registered. FGF23, Klotho, VitD, IGF-1, IGFBP3, and GHBP were measured to evaluate mineral and growth metabolism. Results: 15 patients, 7 male, age 6.9 ± 3.0 y were included. Time on PD was 14.33 ± 12.26 months. Height/age Z score at month 1 was -1.69 ± 1.03. FGF23 and Klotho: 131.7 ± 279.4 y 125.9 ± 24.2 pg/ml, respectively. 8 patients were treated with GH during 6-12 months, showing a non-significant increase in height/age Z-score during the treatment period. Bivariate analysis showed a positive correlation between Klotho and delta ZT/E, and between GHBP vs growth velocity index (p < .05). Conclusions: FGF23 values were high and Klotho values were reduced in children with CKD in PD, comparing to healthy children. Somatotropic axis variables were normal or elevated. rhGH tends to improve height and there is a positive correlation of GHBP and growth velocity in these children.

Peritonitis fúngica por Rhodotorula mucilaginosa en una paciente en diálisis peritoneal automatizada: revisión de la literatura / Fungal peritonitis due to Rhodotorula mucilaginosa in a patient with automated peritoneal dialysis: literature review

Fungal peritonitis is a major complication of peritoneal dialysis associated with high mortality. Most survivors have a high rate of abandonment of peritoneal dialysis. We report a case of fungal peritonitis due to an unusual agent. An 83 year-old woman, with a history of type 2 diabetes mellitus and multiple episodes of bacterial peritonitis associated to technical flaws in the implementation of automated peritoneal dialysis, was admitted due to abdominal pain and cloudy peritoneal fluid. Rhodotorula mucilaginosa was identified in the peritoneal fluid by MALDI-TOF. She was treated with catheter removal and oral posaconazole for 14 days showing clinical resolution and non-recurrence.

La peritonitis fúngica es una complicación mayor de la diálisis peritoneal, con una alta mortalidad asociada y la mayoría de los sobrevivientes presentan una alta tasa de abandono de diálisis peritoneal como terapia de reemplazo renal. Se presenta un caso de peritonitis fúngica por un agente infrecuente. Mujer de 83 años, diabética con múltiples episodios de peritonitis bacteriana asociada a fallas técnicas en la ejecución de diálisis peritoneal automatizada, ingresa por cuadro clínico de dolor abdominal y líquido peritoneal turbio. Se confirmó la presencia de Rhodotorula mucilaginosa en líquido peritoneal mediante MALDI-TOF. Fue tratada con retiro del catéter y posaconazol oral por 14 días, presentando una evolución favorable.

Terapia dialítica no paciente cardiopata / Dialysis therapy in patients with heart disease

A otimização das medidas para controle volêmico tem papel preponderante naabordagem de pacientes com disfunção cardíaca e renal combinada, uma vez quealterações crônicas ou agudas em um desses órgãos, em geral, induzem ou perpetuam anormalidades (funcionais e/ou estruturais) no outro. Esta revisão de literatura propõe uma análise sobre as principais medidas terapêuticas no cardiopata com disfunção renal...

Optimizing the methods used in the control of volemia is very important in the treatment of patients with combined heart and renal dysfunction, as chronic or acute changes in either of these organs generally induces or perpetuates abnormalities (functional and/orstructural) in the other. This literature review analyzes the main therapeutic methods used in heart disease with renal dysfunction...

Adecuación en diálisis peritoneal pediátrica: Del test de equilibrio peritoneal a las aquaporinas / Peritoneal dialysis adequacy in pediatrics: From the peritoneal equilibration test to the aquaporins

La evaluación de las características de transporte de solutos y agua del peritoneo es esencial para adecuar la prescripción dialítica en pacientes portadores de enfermedad renal crónica. Existen una serie de modelos para realizar esta evaluación. El test de equilibrio peritoneal (PET) evalúa la capacidad de transporte del peritoneo clasificando a los pacientes en 4 categorías de transportador: alto, promedio alto, promedio bajo y bajo. El short PET realiza la misma evaluación en solo 2 h, y ha sido validado en pacientes pediátricos. Por otro lado, el MiniPET otorga información adicional al evaluar la capacidad de transporte de agua libre por los poros ultrapequeños, y el Accelerated Peritoneal Examination Time (APEX) evalúa el punto de intersección de las curvas de equilibrio de urea y glucosa, y ha sido propuesto como el tiempo de permanencia óptimo para lograr una UF adecuada. Se analiza la información actual sobre estos métodos diagnósticos, en particular los últimos aportes de la literatura respecto al transporte de agua libre vía aquaporinas, que podrían representar una herramienta importante para optimizar el transporte de agua y solutos en pacientes en diálisis peritoneal crónica, en particular respecto al pronóstico cardiovascular.

An evaluation of the characteristics of peritoneal solute and water transport is essential to assess the suitability of prescribing dialysis in patients suffering from chronic renal disease. There are currently a series of models to perform this evaluation. The peritoneal equilibration test (PET) evaluates the peritoneal transport capacity, classifying the patients into four transport categories: high, high-average, low-average, and low. The short PET enables the same evaluation to be made in only 2 hours, and has been validated in paediatric patients. On the other hand, the MiniPET provides additional information by evaluating the free water transport capacity by the ultra-small pores, and the Accelerated Peritoneal Examination Time (APEX) evaluates the time when the glucose and urea equilibration curves cross, and has been proposed as the optimum dwell time to achieve adequate ultrafiltration. An analysis is presented on the current information on these diagnostic methods as regards free water transport via aquaporins, which could be an important tool in optimising solute and water transport in patients on chronic peritoneal dialysis, particularly as regards the cardiovascular prognosis.

Seguridad y eficacia de paricalcitol en comparación a otros medicamentos en el tratamiento del hiperparatiroidismo secundario en pacientes con enfermedad renal estadío 5 en tratamiento sustitutivo con hemodiálisis o diálisis peritoneal y resistentes a calcitriol / Safety and efficacy of paricalcitol compared to other drugs in the treatment of secondary hyperparathyroidism in patients with stage 5 renal disease undergoing replacement therapy with hemodialysis or peritoneal dialysis and resistant to calcitriol

INTRODUCCIÓN: Antecedentes: El presente informe expone la evaluación del medicamento paricalcitol endovenoso (e.v) y oral, respecto a su uso en pacientes con hiperparatiroidismo secundario a enfermedad renal crónica (ERC) estadío 5 en tratamiento sustitutivo con hemodiálisis o diálisis peritoneal, y resistentes al tratamiento con calcitriol. Aspcetos Generales: El tratamiento del hiprparatiroidismo secundario (HPTs) en la enfermedad rnal crónica se base en el entendimiento de la patogénesis y la clínica de esta condición, y del reconocimiento que la homeostasis aormal del calcio y del fosforo puede incrementar la morbimortalidad. La insuficiencia renal se acompña de una disminución de la absorción del calcio de la excreción de fosfatos. Tecnología Sanitaria de Interés: Paracicalcitol: La reducción de la conversión de la vitamina D a su principal metabolito activo (1,25-hidroxivitamina D) en la Insuficiencia renal conduce a una reducción de la activación del receptor de la vitamina D (VDR), lo cual remueve la supresión inibitoria de la liberación de la hormona paratiroidea (PTH); el incremento sérico de PTH reduce la excreción de calcio e incrementa la resorción del hueso. Paricalcitol es un análogo sintético d ela vitamina D el cual se une y activa al VDR en el riñon, en la glándula paratiroidea, en el intestino y en el hueso; reduciendo así los niveles de PTH y mejorando la momeostasis del calcio y fosforo. METODOLOGÍA: Estrategia de Búsqueda: Se realizó una búsqueda de la literatura con recpecto a la eficacia y seguridad de paricalcitol e.v. y oral para el tratamiento de HPTs en pacientes con enfermedad renal crónica en hemodiálisis o en diálisis peritoneal, y con resistencia al tratamiento con calcitriol, en las bases de datos de OVID MEDLINE y TRIPDATABASE. También se hizo una búsqueda adicional en la página de registro de ensayos clínicos www.clinicaltrials.gov, para poder identificar ensayos en desarrollo o que se hayan realizado y no estén publicados. Adicionalmente, se hizo una búsqueda dentro de la información generada por grupos que realizan revisiones sistemáticas, evaluación de tecnologías sanitarias y guías de práctica clínica, tales como The Cochrane Library, The National Institute for helath and Care Excellence (NICE) y The National Guideline of Clearinghouse. RESULTADOS: Se realizó la búsqueda bibliográfica y de evidencia científica para el sustento del uso de paricalcitol como tratamiento de pacientes con HPTs en hemodiálisis y resistentes al tratamiento con calcitriol. Se presenta la evidencia disponible en guías de práctica clínica, ensayos clínicos no aleatorizados y un estudio registrado en www.clinicalstrials.gov. CONCLUSIONES: En la presente evaluación de tecnología sanitaria no se ha encontrado evidencia que muestre ue el paricaclcitorl ofrezca benefícios para los pacientes en hemodiálisis y resistentes al tratamiento con calcitriol en términos de desenlaces clínicamente relevantes para el paciente establecidos en la pregunta PICO, como la mortalidad, la calidad de vida, hospitalizaciones, eventos cardiovasculares y fracturas. Sin embargo, se ha identificado evidencia aunque proveniente de escasos estudios y de baja calidad, que muestra que paricalcitol puede tener un efecto en reducir los niveles séricos de PTH. Los pacientes de interés en en esta evaluaciónya han sido manejados con calcitriol usando dosis máximas tolerables y por un tiempo determinado, no logrando controlar los niveles bioquímicos de PTH. La situación de no mantener los níveles de PTH dentro de rangos recomendados indicaria persistencia de un recambio óseo anormal asociado a la enfermedad de osteodistrofia renal, por lo que requieren ser manejados con otras opciones terapéuticas disponibles. El Instituto de Evaluación de Tecnoglogías en Salud e Investigación_IETSI, aprueba temporalmente el uso de paricalcitol endovenoso y oral para el tratamiento del HPTs en pacientes en hemodiálisis o en diálisis peritonral y resistentes al tratamiento con calcitriol. Dado que la evidencia que respalda este uso de paricalcitol es aún limitada, se establece que el efecto de paricalcitol se evaluará con los datos de los pacientes que hayan recibido paricalcitol por el lapso de un año para determinar el impacto de su uso en varios desenlaces inclyendo los intermedios como los clínicos. Esta inforamción será tomada en cuenta en la re-evaluación de este medicamento para efectos de un nuevo dictamen al terminar la vigencia del presente Dictamen Preliminar.